Acurx Pharmaceuticals, Inc.
ACXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001736243
No open-market purchases or sales by Acurx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 18 institutions reported holding it in 13F filings for Q2 2026, worth $185.5K in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Acurx Pharmaceuticals, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 12 | 13 | +1 |
| Shares | 538.6K | 1.49M | +946.4K (+175.7%) |
| Value | $1.86M | $3.94M | +$2.07M (+111.3%) |
New holders (3)
Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| One68 Global Capital, LLC | 13,044 | $34.6K | 0.21% |
| Salem Investment Counselors Inc | 100 | $265 | 0.00% |
| Royal Bank of Canada | 121 | $0 | 0.00% |
Sold out (2)
Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Belpointe Asset Management LLC | 3,000 | $10.4K |
| UBS Group AG | 2,904 | $10.0K |